A study of the specificity of lymphocytes in nevirapine-induced skin rash

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 3, 2009, Pages 836-841

  Chen, Xin ^a   Tharmanathan, Tharsika ^b   Mannargudi, Baskar ^a   Gou, Hong ^a   Uetrecht, Jack P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXY NEVIRAPINE; 4 CHLORO NEVIRAPINE; ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; NEVIRAPINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ERUPTION; FEMALE; LYMPH NODE; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; BROWN NORWAY RAT; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; HYDROXYLATION; IMMUNOLOGY; PATHOLOGY; RASH; SECRETION;

ANIMALS; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HYDROXYLATION; LYMPHOCYTES; MOLECULAR STRUCTURE; NEVIRAPINE; RATS; RATS, INBRED BN; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 73349088732     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.157362     Document Type: Article

References (16)

1. Chen J, Mannargudi BM, Xu L, and Uetrecht J (2008) Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem Res Toxicol 21:1862-1870.
2. Drummond NS, Vilar FJ, Naisbitt DJ, Hanson A, Woods A, Park BK, and Pirmohamed M (2006) Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis. Antivir Ther 11:393-395.
3. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC, and EuroSCAR Study Group (2001) Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15:1843-1848.
4. Grozinger KG, Fuchs V, Hargrave KD, Mauldin S, Vitous J, Campbell S, and Adams J (1995) Synthesis of nevirapine and its major metabolite. J Heterocycl Chem 32:259-263.
5. Keane NM, Nolan D, Phillips EJ, Lucas AD, Almeida CA, Martin AM, Netto JD, Marriott D, Purcell T, and Mallal S (2007) Use of the ELISpot assay to detect abacavir- and nevirapine-induced IFN-γ responses in PBMC from HIV-infected patients with abacavir or nevirpine hypersensitivity reactions. In Proceedings of the 4th International AIDS Society Meeting; 2007 Jul 22-25; Sydney, Australia. Abstract MOPEB007. International AIDS Society, Geneva, Switzerland.
6. Hargrave KD, Proudfoot JR, Grozinger KG, Cullen E, Kapadia SR, Patel UR, Fuchs VU, Mauldin SC, Vitous J, and Behnke ML (1991) Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J Med Chem 34:2231-2241.
7. Kelly TA, Proudfoot JR, McNeil DW, Patel UR, David E, Hargrave KD, Grob PM, Cardozo M, Agarwal A, and Adams J (1995) Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2, 4-disubstituted analogs of nevirapine. J Med Chem 38:4839-4847.
8. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, et al. (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 8:186-195.
9. Norman MH, Chen N, Chen Z, Fotsch C, Hale C, Han N, Hurt R, Jenkins T, Kincaid J, Liu L, et al. (2000) Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists. J Med Chem 43:4288-4312.
10. Popovic M, Caswell JL, Mannargudi B, Shenton JM, and Uetrecht JP (2006) Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats. Chem Res Toxicol 19:1205-1214.
11. Shenton JM, Popovic M, Chen J, Masson MJ, and Uetrecht JP (2005) Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem Res Toxicol 18:1799-1813.
12. Shenton JM, Teranishi M, Abu-Asab MS, Yager JA, and Uetrecht JP (2003) Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem Res Toxicol 16:1078-1089.
13. Taiwo BO (2006) Nevirapine toxicity. Int J STD AIDS 17:364-369.
14. Uetrecht JP (2007) Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47:513-539.
15. Warren KJ, Boxwell DE, Kim NY, and Drolet BA (1998) Nevirapine-associated Stevens-Johnson syndrome. Lancet 351:567.
16. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, Valitutti S, and Pichler WJ (1998) HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 102:1591-1598.